Sign in
Active, not recruitingNo phase

Delirium in Children Undergoing Stem Cell Transplantation

Key facts

Who runs it
Weill Medical College of Cornell University
Where
Boston, Memphis, New York, Philadelphia, and San Francisco, United StatesSee the 5 sitesAlso in 1 other country, 1 site
Trial code
Status
Active, not recruiting
People taking part
1,040 people enrolled
Started
12 Jul 2021
Expected to end
31 Jul 2027
Type of study
Observational
Treatments tested
  • Daily screening for delirium
Record updated
23 October 2026

Who can take part

Age
Up to 21 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Age 0-21 years old
  • Admitted for purpose of stem cell transplant

Who cannot take part

  • Admitted for reason other than stem cell transplant (example: late post-transplant complications)
  • Age >21 years old

Where in United States

Also in 1 other country, 1 site

  • Dana Farber Cancer CenterBoston, United States
  • St. Jude Children's Research HospitalMemphis, United States
  • Weill Cornell Medical CollegeNew York, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • University of California San FranciscoSan Francisco, United States

About the trial

What the trial wants to find out

Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes. Our eventual goal is to reduce delirium in this population.

The group in the trial

  • Pediatric Stem Cell Transplant Patients

    A consecutive cohort of children admitted to the hospital for stem cell transplantation

    Treatment: Daily screening for delirium

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Delirium in Children Undergoing Stem Cell Transplantation: Epidemiology and Outcomes
Record updated
23 October 2026